243 Users Online
Treatment Syndromes Dementia Movement Disorders Market Segmented By Progressive Dementia, Neurological Abnormalities, Disorder Syndrome
Chapter 1. Preface
1.1. Report Description
1.2. Research Methodology
1.3. Assumptions
Chapter 2. Market Synopsis
Chapter 3. Porter’s Five Forces Analysis
3.1. Bargaining Power of Suppliers
3.2. Bargaining Power of Buyers
3.3. Threat of New Entrants
3.4. Threat of Substitutes
3.5. Intensity of Rivalry
Chapter 4. Industry Overview
4.1. Market Definition
4.2. Market Drivers
4.2.1. Increasing prevalence of neurodegenerative diseases
4.2.2. Rising awareness about mental diseases
4.2.3. Increasing R&D investments in drug discovery and developments
4.3. Impact Analysis of Market Drivers
4.4. Market Restraints
4.4.1. Strict regulatory requirements and long approval time for drugs
4.4.2. Lack of comprehensive therapeutic management of dementia and movement disorders
4.5. Impact Analysis of Market Restraints
4.6. Market Trend
4.6.1. Rising number of collaborations and partnerships would lead to rise in research and discovery of dementia and movement disorder drugs
Chapter 5. Global Market Size and Forecast
Chapter 6. Market Size and Forecast by Drugs Used to Treat Progressive Dementia
6.1. Diseases Based Therapeutics Under Progressive Dementia
6.2. Drugs for Progressive Dementia
Chapter 7. Market Size and Forecast by Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities
7.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
7.2. Drugs for Progressive Dementia
Chapter 8. Market Size and Forecast by Drugs Used to Treat Movement Disorder Syndrome
8.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
8.2. Drugs for Movement Disorder Syndrome
Chapter 9. Market Size and Forecast by Geography
9.1. North America
9.2. Europe
9.3. Asia
Chapter 10. Competitive Scenario
10.1. Competitive Benchmarking
Chapter 11. Company Profiles
11.1. F. Hoffmann-La Roche, Ltd.
11.1.1. Company overview
11.1.2. Products and services
11.1.3. Financial performance
11.1.4. Key developments
11.2. Baxter
11.2.1. Company overview
11.2.2. Products and services
11.2.3. Financial performance
11.2.4. Key development
11.3. Novartis AG
11.3.1. Company overview
11.3.2. Products and services
11.3.3. Financial performance
11.3.4. Key developments
11.4. Merck & Co., Inc.
11.4.1. Company overview
11.4.2. Products and services
11.4.3. Financial performance
11.4.4. Key developments
11.5. Sanofi
11.5.1. Company overview
11.5.2. Products and services
11.5.3. Financial performance
11.5.4. Key developments
11.6. Pfizer, Inc.
11.6.1. Company overview
11.6.2. Products and services
11.6.3. Financial performance
11.6.4. Key developments
11.7. Valeant Pharmaceuticals International, Inc.
11.7.1. Company overviews
11.7.2. Products and services
11.7.3. Financial performance
11.7.4. Key developments
11.8. AstraZeneca GmbH
11.8.1. Company overview
11.8.2. Products and services
11.8.3. Financial performance
11.8.4. Key developments
11.9. Abbott Laboratories, Inc.
11.9.1. Company overview
11.9.2. Products and services
11.9.3. Financial performance
11.9.4. Key developments
11.10. Bristol-Myers Squibb Company
11.10.1. Company overview
11.10.2. Products and services
11.10.3. Financial performance
11.10.4. Key developments
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
List of Tables
TABLE 1: Market snapshot: Treatment for syndromes of dementia and movement disorders market, 2014 and 2020
TABLE 2: Drivers for global treatment for syndrome of dementia and movement disorders market: Impact analysis
TABLE 3: Estimated average timelines for clinical trial approval in various countries
TABLE 4: Restraints for global treatment for syndromes of dementia and movement disorders market: Impact analysis
TABLE 5: Major collaborations and partnerships by dementia and movement disorder treatment companies (2011 – 2013)
TABLE 6: Global treatments for syndromes of dementia and movement disorders market size, by region, 2010 – 2013 (USD million)
TABLE 7: Global treatments for syndromes of dementia and movement disorders market size, by region, 2014 – 2020 (USD million)
TABLE 8: Global treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)
TABLE 9: Global treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)
TABLE 10: Global progressive dementia therapeutic market size, by disease, 2010 – 2013 (USD million)
TABLE 11: Global progressive dementia therapeutic market size, by disease, 2014 – 2020 (USD million)
TABLE 12: Global progressive dementia market size, by drug category, 2010 – 2013 (USD million)
TABLE 13: Global progressive dementia market size, by drug category, 2014 – 2020 (USD million)
TABLE 14: Global progressive dementia with other neurological abnormalities therapeutics market size, by disease, 2010 – 2013 (USD million)
TABLE 15: Global progressive dementia with other neurological abnormalities therapeutic market size, by disease, 2014 – 2020 (USD million)
TABLE 16: Global progressive dementia with other neurological abnormalities market size, by drug category, 2010 – 2013 (USD million)
TABLE 17: Global progressive dementia with other neurological abnormalities market size, by drug category, 2014 – 2020 (USD million)
TABLE 18: Global movement disorder syndrome therapeutics market size, by disease, 2010 – 2013 (USD million)
TABLE 19: Global movement disorder syndrome therapeutics market size, by disease, 2014 – 2020 (USD million)
TABLE 20: Global movement disorders market size, by drug category, 2010 – 2013 (USD million)
TABLE 21: Global movement disorder market size, by drug category, 2014 – 2020 (USD million)
TABLE 22: The North American treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)
TABLE 23: The North American treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)
TABLE 24: The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)
TABLE 25: The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)
TABLE 26: The European treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)
TABLE 27: The European treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)
TABLE 28: The European treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)
TABLE 29: The European treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)
TABLE 30: The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)
TABLE 31: The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)
TABLE 32: The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)
TABLE 33: The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)
TABLE 34: F. Hoffmann-La Roche, Ltd.’s product categories
TABLE 35: Baxter’s product categories
TABLE 36: Novartis AG’s product categories
TABLE 37: Merck & Co., Inc.’s product categories
TABLE 38: Sanofi’s product categories
TABLE 39: Pfizer, Inc.’s product categories
TABLE 40: Valeant Pharmaceuticals International, Inc.’s product categories
TABLE 41: AstraZeneca GmbH’s product categories
TABLE 42: Abbott Laboratories, Inc.’s product categories
TABLE 43: Bristol-Myers Squibb Company’s product categories
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
List of Figures
FIG. 1: Treatment for syndromes of dementia and movement disorders market: Porter’s five forces analysis
FIG. 2: Types of dementia and movement disorders 18
FIG. 3: Global treatments for syndromes of dementia and movement disorders market share, by region, by value, 2013
FIG. 4: Global treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013
FIG. 5: Global progressive dementia therapeutic market share, by disease, by value, 2013
FIG. 6: Global progressive dementia market share, by drug category, by value, 2013
FIG. 7: Global progressive dementia with other neurological abnormalities therapeutics market share, by disease, by value, 2013
FIG. 8: Global progressive dementia with other neurological abnormalities market share, by drug category, by value, 2013
FIG. 9: Global movement disorder syndrome therapeutics market share, by disease, by value, 2013
FIG. 10: Global movement disorder syndrome market share, by drug category, by value, 2013
FIG. 11: The North American treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013
FIG. 12: The North American treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013
FIG. 13: The European treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013
FIG. 14: The European treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013
FIG. 15: The Asian treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013
FIG. 16: The Asian treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013
FIG. 17: Competitive landscape of treatment providers for syndromes of dementia and movement disorders, 2013
FIG. 18: F. Hoffmann-La Roche, Ltd.’s sales and net income, 2011 – 2013 (USD million)
FIG. 19: Baxter’s net sales and net income, 2011 – 2013 (USD million)
FIG. 20: Novartis AG’s net sales and net income, 2011 – 2013 (USD million)
FIG. 21: Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)
FIG. 22: Sanofi net sales and net income, 2011 – 2013 (USD million)
FIG. 23: Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)
FIG. 24: Valeant Pharmaceuticals International, Inc.’s revenues and net income/loss, 2011 – 2013 (USD million)
FIG. 25: AstraZeneca GmbH’s revenues and profit, 2011 – 2013 (USD million)
FIG. 26: Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million)
FIG. 27: Bristol-Myers Squibb’s revenue and net earnings, 2011 – 2013 (USD million)
